Cellworks’ Study Predicts Immune Checkpoint Inhibitor Resistance in Patients with High Microsatellite Instability
Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Best-in-Class PTRS, today announced compelling results from a new study demonstrating the ability of the Cellworks Platform to identify patients with high microsatellite instability (MSI-H) who may not respond to immune checkpoint inhibitors (ICIs), despite MSI-H status. Results from the study were showcased in a poster presentation titled, Use of Biosimulation to Predict Immune Checkpoint Inhibitor Resistance in Patients with High Microsatellite Instability as part of the AACR Annual Meeting 2025 taking place April 25-30, 2025 at the McCormick Place Convention Center in Chicago.
Cellworks Enhances TRI with Personalized Tumor Microenvironment Modeling to Predict Overall Survival in NSCLC Patients Receiving Immunotherapy
Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced results from a study demonstrating the efficacy of the Cellworks Therapy Response Index (TRI) combined with personalized tumor microenvironment (TME) modeling in predicting overall survival (OS) for non-small cell lung cancer (NSCLC) patients receiving immunotherapy (IO). This comprehensive approach enables more precise identification of patient-specific dysregulation in immunotherapy signaling pathways, resulting in better predictions of treatment responses.
Cellworks Biosimulation Predicts PARPi Benefit in Patients with Ovarian, Pancreatic, Prostate and Triple-Negative Breast Cancers
Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced results from a study using the Cellworks Platform to predict homologous recombination deficiency (HRD) and the effectiveness of PARP inhibitors (PARPi) in real-world cohorts of patients with ovarian, pancreatic, prostate, and triple-negative breast cancers (TNBC). This research highlights the potential of the Cellworks mechanistic biosimulation model to go beyond BRCA mutation status and provide more comprehensive predictions of patient response to PARPi therapies.
Cellworks Biosimulation Combined with Tumor Microenvironment Modeling Enhances Predictions of IO Response in NSCLC Patients
Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced results from a study using Cellworks computational biosimulation to predict how individual non-small cell lung cancer (NSCLC) patients will respond to immunotherapy (IO) treatment by combining biosimulation with personalized tumor microenvironment (P-TME) modeling. The research found that biosimulation is highly effective for predicting immunotherapy responses in NSCLC above and beyond PD-L1 and TMB.
Cellworks Biosimulation Identifies which NSCLC Patients will Benefit from Combining Chemotherapy with Immunotherapy
Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced results from a study, where Cellworks' biosimulation platform accurately predicted overall survival (OS) and chemotherapy benefit in two real-world non-small cell lung cancer (NSCLC) patients cohorts. The study showcases Cellworks’ ability to advance personalized cancer treatment by identifying NSCLC patients most likely to benefit from combining immunotherapy and chemotherapy, regardless of their PD-L1 levels, thereby optimizing treatment strategies and improving patient outcomes.
Cellworks Biosimulation Predicts Chemotherapy Benefit in Osimertinib-treated NSCLC Patients with EGFR Mutations
Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced findings from a study using the Cellworks Platform to predict the benefits of adding chemotherapy to osimertinib treatment in patients with EGFR mutated non-small cell lung cancer (NSCLC). Leveraging data from a real-world retrospective cohort, the biosimulation study confirmed that adding chemotherapy to osimertinib led to a higher predicted overall response rate (ORR). The study revealed that while all patients responded to the addition of chemotherapy, the magnitude of benefit varied among individuals and was intricately determined by underlying genomic abnormalities, enabling the identification of patients who would benefit from combination therapies, and others who would achieve similar outcomes without the addition of chemotherapy.
Dr. Michael Donovan Joins Cellworks to Oversee Personalized Cancer Therapy Biosimulation in New CLIA-Certified Lab
Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced it has opened a CLIA-certified computational laboratory in Franklin, Tennessee. CLIA (Clinical Laboratory Improvement Amendments) is administered under the Centers for Medicare and Medicaid Services and provides oversight for clinical lab testing in the United States. Prominent academic and biotech leader Dr. Michael Donovan, PhD MD, has joined Cellworks as Laboratory Director to spearhead computational biosimulation efforts for delivering Personalized Therapy Decision Support reports within the newly registered CLIA lab.
Cellworks Personalized Therapy Biosimulation Study Produces Superior OS and DFS Predictions for Gastroesophageal Cancer Patients
Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced the results from a real-world study of gastroesophageal cancer which found that Therapy Response Index (TRI) scores generated using the Cellworks Biosimulation Platform predicted overall survival (OS) above and beyond standard clinical factors, including patient age, sex, and tumor-node-metastasis (TNM) staging. The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).
